@article {Bingle1273, author = {L. Bingle and T. D. Tetley}, title = {Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation.}, volume = {51}, number = {12}, pages = {1273--1274}, year = {1996}, doi = {10.1136/thx.51.12.1273}, publisher = {BMJ Publishing Group Ltd}, abstract = {Secretory leukoprotease inhibitor (SLPI) is a low molecular weight serine proteinase inhibitor, notably of neutrophil elastase (NE), which is synthesised and secreted by the pulmonary epithelium. SLPI plays an important role in limiting NE-induced pulmonary inflammation and, significantly, it also possesses anti-HIV activity. SLPI is a significant component of the anti-NE shield in the lung which has different reactivity from, and is therefore complementary to, the anti-NE action of alpha 1-proteinase inhibitor (alpha 1-PI). Inhaled recombinant SLPI (rSLPI) could prove beneficial in partnership with alpha 1-PI in the treatment of a number of inflammatory lung disorders including emphysema, chronic bronchitis, cystic fibrosis, and adult respiratory distress syndrome.}, issn = {0040-6376}, URL = {https://thorax.bmj.com/content/51/12/1273}, eprint = {https://thorax.bmj.com/content/51/12/1273.full.pdf}, journal = {Thorax} }